Publicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (41)

2024

  1. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

    Blood, Vol. 144, Núm. 16, pp. 1722-1731

  2. Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia

    Blood Cancer Journal

  3. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

    British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535

  4. WHO/ICC Classification for Myelodysplastic Neoplasms/Syndromes Performs Better for Subtype Cytomorphological Diagnosis?

    Diagnostics, Vol. 14, Núm. 15

2023

  1. A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia

    British Journal of Haematology, Vol. 201, Núm. 2, pp. 302-307

  2. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

    Leukemia

  3. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

    HemaSphere, Vol. 7, Núm. 10, pp. E961

  4. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

    Cell Reports Medicine, Vol. 4, Núm. 12

  5. NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition

    British Journal of Haematology, Vol. 201, Núm. 3, pp. 470-479

2022

  1. Persistent Large Granular Lymphocyte Clonal Expansions: “The Root of Many Evils”—And of Some Goodness

    Cancers, Vol. 14, Núm. 5

  2. Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study

    Blood Cancer Journal

2021

  1. Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival

    International Journal of Cancer, Vol. 148, Núm. 8, pp. 1887-1894

  2. Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?

    International Journal of Cancer, Vol. 148, Núm. 7, pp. 1616-1624

  3. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma

    Journal of Thrombosis and Thrombolysis, Vol. 52, Núm. 3, pp. 848-853

  4. Minimal residual disease in multiple myeloma: Something old, something new

    Cancers, Vol. 13, Núm. 17

  5. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717

2020

  1. Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach

    OncoImmunology, Vol. 9, Núm. 1

  2. Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms

    Blood Cancer Journal, Vol. 10, Núm. 8

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

  2. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

    Leukemia